- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07470320
Biologia Placentária na Saúde e na Doença
Pre-eclampsia (PET) is a condition characterised by high blood pressure and damage to other organs, and is a leading cause of maternal and fetal complications such as fetal growth restriction (FGR). Gestational diabetes mellitus (GDM) involves abnormal blood sugar levels during pregnancy and can have both short and long-term impacts on the health of the mother and child. Both conditions are linked to placental dysfunction but the precise mechanisms behind these links remain unclear.
A major focus of this study is on extracellular vesicles (EVs) which are tiny, bubble-like particles released by the placenta into the mother's and baby's bloodstreams. These EVs act as messengers, carrying proteins, lipids and genetic material that can influence how cells function, even in parts of the body far from the placenta. Notably, the number and content of these EVs change in conditions like PET and GDM, suggesting they may play a role in the development of these complications.
This single-site, observational, laboratory study aims to investigate how these EVs contribute to maternal health and disease. To enable analysis across different physiological and pathological conditions pregnant participants with healthy pregnancies, pregnancies predisposed to PET and pregnancies complicated by GDM, FGR and PET will be recruited alongside healthy non-pregnant controls. Recruitment will be from the Oxford University Hospitals NHS Foundation Trust and the Nuffield Department of Women's and Reproductive Health, University of Oxford (who fund the research). Demographic and clinical data will be collected as well as blood, urine, breath, voice, placenta, umbilical cord, umbilical cord blood, amniotic fluid and/or uterine vein blood samples.
Through examining EV content and function, it is hoped a better understanding of their role in pregnancy complications will be gained, including their potential as non-invasive biomarkers for early detection and targeted treatments, improving outcomes for mothers and babies worldwide.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The study is a non-interventional, observational study focused on sample collection and laboratory-based analyses to investigate the role of placental EVs and soluble factors in maternal and fetal health. The study will focus on understanding the molecular mechanisms underlying pre-eclampsia, gestational diabetes mellitus and fetal growth restriction, with the ultimate aim of identifying biomarkers and therapeutic targets. To achieve this, the study will recruit participants with healthy, pathological and predisposed pregnancies alongside non-pregnant healthy controls.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Professor Manu Vatish
- Número de telefone: +441865 221009
- E-mail: manu.vatish@wrh.ox.ac.uk
Locais de estudo
-
-
-
Oxford, Reino Unido
- Recrutamento
- Oxford University Hospitals NHS Foundation Trust
-
Contato:
- Clinical Research Group
- Número de telefone: +441865 221107
- E-mail: clinicalresearchgroup@wrh.ox.ac.uk
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
This study will recruit a diverse cohort of pregnant and non-pregnant participants to enable analysis of placental EVs and soluble factors across different physiological and pathological conditions.
Participants will include:
- Pregnant women with pre-eclampsia, gestational diabetes mellitus or fetal growth restriction to allow the study of disease-specific alterations in EVs and systemic responses.
- Pregnant women predisposed to pre-eclampsia to provide insights into risk factors and early-stage changes, aiding in biomarker discovery for prediction and prevention.
- Pregnant women with healthy pregnancies to understand normal EV release and immune regulation.
- Non-pregnant women to provide critical baseline data to differentiate the effects of pregnancy from underlying physiological processes.
Pregnant participants may be recruited at any gestational stage to ensure a comprehensive coverage of pregnancy progression.
Descrição
Inclusion Criteria:
-
Female, aged 18 years or above
-
Willing and able to give informed consent for participation in the study
-
Able to read and understand written and spoken English to comprehend study materials and give informed consent
-
Non-pregnant women in good general health OR pregnant women who fall into one of the following:
- Healthy pregnancy
- Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria
- Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy
- Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities
- Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies
Exclusion Criteria:
- Non-pregnant participants with active health conditions that could confound study outcomes
- Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: OTHER
- Perspectivas de Tempo: OTHER
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Mulheres grávidas diagnosticadas com pré-eclâmpsia
|
There are no interventions for this study |
|
Mulheres grávidas diagnosticadas com diabetes mellitus gestacional
|
There are no interventions for this study |
|
Mulheres grávidas diagnosticadas com restrição do crescimento fetal
|
There are no interventions for this study |
|
Mulheres grávidas saudáveis
|
There are no interventions for this study |
|
Mulheres saudáveis não grávidas
|
There are no interventions for this study |
|
Mulheres grávidas predispostas à pré-eclâmpsia
|
There are no interventions for this study |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Enhanced understanding of the molecular and cellular mechanisms linking placental EVs to maternal systemic inflammation in PET and GDM.
Prazo: Baseline and at delivery
|
Quantitative (number of particles/ml) and qualitative differences (protein cargo) in EV profiles |
Baseline and at delivery
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Quantitative and qualitative differences in inflammatory immune cells
Prazo: baseline and delivery
|
Quantitative (cells/ml) and qualitative (protein and RNA composition/mg cell) will be measured |
baseline and delivery
|
|
Sensitivity, specificity and predictive value of EVs for identifying PET, GDM and other pregnancy complications
Prazo: Baseline and delivery
|
Standard statistical analysis of EV parameters against clinical endpoints to derive sensitivity, specificity and PPV/NPV in these disease conditions |
Baseline and delivery
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças do Sistema Endócrino
- Doenças Vasculares
- Doenças cardiovasculares
- Processos Patológicos
- Doenças urogenitais femininas e complicações na gravidez
- Doenças Metabólicas
- Complicações na Gravidez
- Distúrbios do Metabolismo da Glicose
- Diabetes Mellitus
- Doenças Fetais
- Distúrbios do crescimento
- Hipertensão
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Condições Patológicas, Sinais e Sintomas
- Doenças Nutricionais e Metabólicas
- Diabetes Gestacional
- Pré-eclâmpsia
- Retardo do crescimento fetal
- Hipertensão Induzida pela Gravidez
Outros números de identificação do estudo
- 18939
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .